A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
R-Pharm
Dispatch Biotherapeutics
Context Therapeutics Inc.
Kivu Bioscience Inc.
Novartis
Kumquat Biosciences Inc.
Seagen Inc.
Seagen Inc.
Pliant Therapeutics, Inc.
Pfizer
Eli Lilly and Company
Pfizer
Bristol-Myers Squibb
Eli Lilly and Company
Eli Lilly and Company
Kivu Bioscience Inc.
Genentech, Inc.
AstraZeneca
MOMA Therapeutics
Astellas Pharma Inc
Kura Oncology, Inc.
Boehringer Ingelheim
Hoffmann-La Roche
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
OncoC4, Inc.
Revolution Medicines, Inc.
Novartis
Seagen Inc.
Vividion Therapeutics, Inc.
Fate Therapeutics
Coherus Oncology, Inc.
Alterome Therapeutics, Inc.
AstraZeneca
Zumutor Biologics Inc.
Novartis
Hoffmann-La Roche
IDEAYA Biosciences
Erasca, Inc.
ImmVirx Pty Ltd
Novartis
GlaxoSmithKline
Pfizer
Incyte Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Orano Med LLC
EMD Serono